Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies

Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech

  PR Newswire

  LONDON, February 26, 2013

LONDON, February 26, 2013 /PRNewswire/ --

According to the World Health Organization and CDC, more than 500 million
people worldwide and approximately one-third of American adults (more than 78
million people) are obese. In addition to obesity, high cholesterol, blood
pressure and triglycerides are significant risk factors for cardiovascular
disease. Biotechnology companies like Vivus Inc. (NASDAQ: VVUS) and Achillion
Pharmaceuticals Inc. (NASDAQ: ACHN) would be instrumental in providing cure
and medicines for growing number of diseases. StockCall has posted free
technical research on VIVUS Inc. and Achillion Pharmaceutical which can be
downloaded upon sign up at

Vivus Inc. announces publication of an encouraging study on Qsymia

Vivus Inc. is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health for U.S., Europe and other world markets.
The company announced the publication of a study concluding that weight loss
resulting from treatment with Qsymia™(phentermine and topiramate
extended-release) capsules CIV led to significant improvements in cholesterol,
blood pressure and triglycerides in obese and overweight patients experiencing
one or more of these associated conditions. The improvements were
significantly greater among patients who lost 10% or more of their starting
weight. Sign up and read the complimentary report on VIVUS Inc. at

"This provides clear evidence that patients with hypertension or high
cholesterol treated with Qsymia for one year experienced significant weight
loss and clinically meaningful improvements in their underlying cardiovascular
risk factors," said Suzanne Oparil, M.D., Director of the Vascular Biology and
Hypertension Program, University of Alabama at Birmingham, and an investigator
in the study.

At Vuvus, Qsymia is in phase 2 clinical development for the treatment of type
2 diabetes and obstructive sleep apnea. Qsymia is approved in the U.S. and is
indicated as an adjunct to a reduced-calorie diet and increased physical
activity for chronic weight management in adults with an initial body mass
index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight)
in the presence of at least one weight-related medical condition such as high
blood pressure, type 2 diabetes, or high cholesterol.

Achillion Pharmaceuticals announces pricing of public offering of common stock

Achillion Pharmaceuticals Inc. is an innovative pharmaceutical company
dedicated to bringing important new treatments to patients with infectious
diseases and is focused on solutions for the most challenging problems in
infectious disease including HCV and resistant bacterial infections. The
company announced today the pricing of an underwritten public offering of
15,000,000 shares of its common stock at a price to the public of $8.40 per
share. The net proceeds to Achillion from the sale of the shares, after
deducting underwriting discounts and commissions and estimated offering
expenses, are expected to be approximately $118.5 million. The free report on
Achillion Pharmaceuticals Inc. can be downloaded by signing up now at

The offering is expected to close on February 27, 2013, subject to customary
closing conditions. Citigroup and Leerink Swann LLC are acting as joint
book-running managers, and JMP Securities LLC, Piper Jaffray & Co. and Wells
Fargo Securities, LLC are acting as co-managers for the offering.

Achillion has granted the underwriters a 30-day option to purchase up to an
additional 2,250,000 shares of its common stock. The expected net proceeds to
Achillion referenced above do not include any net proceeds that Achillion
would receive if the underwriters exercise such option.

About is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

Contact: William T. Knight, Email:, Contact Number:
+1(646)-396-9857 (9:00 am EST - 01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.